Cemag Invest
VC Fund
Paris, France
Cemag Invest is a family office founded in 2016 dedicated to minority capital development investments in the fields of healthcare, B to B services, and technology.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Cemag Invest invests in
Stages Cemag Invest invests in
Countries Cemag Invest invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $7.5M–$11M
- Series B
- $7.9M–$34M
- Private Equity
- $17M–$18M
Investment Focus
Industry
- Medical 3 (23%)
- Health Care 3 (23%)
- Artificial Intelligence 3 (23%)
- Manufacturing 2 (15%)
- Medical Device 2 (15%)
Stage
- Series B 4 (31%)
- Series A 2 (15%)
- Private Equity 2 (15%)
- Seed 1 (8%)
- Series C 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Catherine Dunand
President and Founder
|
President and Founder | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $1.7M / Post-IPO Debt / Jun 22, 2026 | ||
| Wandercraft develops autonomous walking exoskeletons and robotic systems designed to restore upright mobility to individuals with walking impairments. The company offers devices such as Atalante X, a hands‑free, self‑balancing exoskeleton used in rehabilitation centers, and a Personal Exoskeleton prototype that leverages AI‑driven balance tosupport walking in daily life. Their systems incorporate real‑time adaptive gait algorithms and powered joints to facilitate multidirectional movement and support early intensive rehabilitation. Wandercraft collaborates with healthcare institutions and has initiated clinical trials to evaluate safety and effectiveness in managing spinal cord injuries and stroke rehabilitation. | $75M / Series D / Jun 06, 2025 | ||
| Diabeloop is a medical device company for diabetes and closed-loop system. It also develops disruptive technological innovations to automate the treatment of diabetes.The company mission is to make accessible disruptive technological innovations that will allow people with type 1 diabetes to live the life they want. Diabeloop was founded in 2015and is headquartered in Grenoble, Auvergne-Rhône-Alpes, France. | $16.3M / Venture - Series Unknown / Mar 04, 2024 | ||
| Oso is a business that focuses on ambient intelligence for careers and persons in vulnerable situations. Oso is healthcare and well-being from human noises. | $11M / Series A / Apr 20, 2023 | ||
| Avicenna.ai is an innovative medical device company. Avicenna.ai develops new generation of algorithms dedicated to the detection of life threatening lesions. | $7.5M / Series A / Feb 08, 2023 | ||
| Wandercraft develops autonomous walking exoskeletons and robotic systems designed to restore upright mobility to individuals with walking impairments. The company offers devices such as Atalante X, a hands‑free, self‑balancing exoskeleton used in rehabilitation centers, and a Personal Exoskeleton prototype that leverages AI‑driven balance tosupport walking in daily life. Their systems incorporate real‑time adaptive gait algorithms and powered joints to facilitate multidirectional movement and support early intensive rehabilitation. Wandercraft collaborates with healthcare institutions and has initiated clinical trials to evaluate safety and effectiveness in managing spinal cord injuries and stroke rehabilitation. | $45.3M / Series C / Jan 20, 2022 | ||
| Aryballe Technologies was created in Grenoble/France by a team of scientists and entrepreneurs. As a technology platform their main objectives are to develop new generations of universal sensors which can be adapted to different applications.In parallel to their core hardware development activities they are also organized to handle thesoftware + database development and full manufacturing of their sensors and devices. | $7.9M / Series B / Jul 10, 2020 | ||
| Avicenna.ai is an innovative medical device company. Avicenna.ai develops new generation of algorithms dedicated to the detection of life threatening lesions. | $3M / Seed / Feb 07, 2020 | ||
| Diabeloop is a medical device company for diabetes and closed-loop system. It also develops disruptive technological innovations to automate the treatment of diabetes.The company mission is to make accessible disruptive technological innovations that will allow people with type 1 diabetes to live the life they want. Diabeloop was founded in 2015and is headquartered in Grenoble, Auvergne-Rhône-Alpes, France. | $34.3M / Series B / Dec 02, 2019 | ||
| Cosmo Tech is a global technology company that helps the C-suite make optimal business decisions. The company was founded in 2010 by Michel Morvan and Hugues de Bantel.Then known as The CoSMo Company, the Lyon-based startup quickly established itself as a global reference in the modeling and simulation of complex systems. The company’s innovativeapproach to complexity and capacity to model any complex system in any industry quickly set the company on the path to success.Cosmo Tech has been recognised publicly for its industry-validated software including being named a Cool Vendor in Data Science by Gartner in 2016, recognised as France’s Most Innovative Software Company by EY and Syntec in 2016, named to the Cleantech Global 100 in 2017, and named to both the Red Herring 100 Europe and Red Herring 100 USA lists in 2017.In 2014 the company raised $5.2 million in Series A funding, expanded operations to the US, and opened its San Francisco office. In 2017 the company raised an additional $3.1 million in a follow-on round and was rebranded as Cosmo Tech.Today Cosmo Tech has a diverse team of more than 70 employees serving clients in Europe and North America. | $24.4M / Series B / Sep 11, 2018 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Cemag Invest invest in?
Cemag Invest invests primarily in Medical, Health Care and Artificial Intelligence startups, most often at Series B and Series A stage. Most of the 13 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Cemag Invest's check size?
Cemag Invest typically joins rounds of $7.5M–$11M at Series A, $7.9M–$34M at Series B and $17M–$18M at Private Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cemag Invest participates in.
How do I contact Cemag Invest?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cemag Invest?
The team at Cemag Invest includes Catherine Dunand (President and Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
